New hope for kidney cancer: which drug combo works best after immunotherapy fails?
NCT ID NCT05012371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two different drug treatments in people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of lenvatinib and everolimus or cabozantinib alone. The goal is to see which approach better controls the cancer and improves quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
- New PET scan could reveal kidney cancer drug success in weeks, not months
- Cell therapy combo aims to boost kidney cancer treatment